Merck & Co., Inc.

Equities

MRK

US58933Y1055

Market Closed - Nyse Other stock markets 21:00:02 11/07/2025 BST			After hours 01:00:00
83.36 ^USD	-0.79%		83.05	-0.37%

07-11	Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy	RE
07-11	Global markets live: Tesla, Nvidia, Google, BP, Nissan…

Merck & Co., Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10:00 AM

Published on 10/06/2025 at 16:35, updated on 10/06/2025 at 18:05

Presenter Speech
Unknown Analyst (Analysts)

Let's get started. Very excited to welcome Merck to our next session, Rob Davis, Chairman and CEO; Dean Li, EVP and President of Merck Research Labs.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Merck & Co., Inc.

Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy	07-11	RE
Global markets live: Tesla, Nvidia, Google, BP, Nissan…	07-11
MERCK : Jefferies raises TP after Verona acquisition	07-11	CF
FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports	07-11	MT
Wall Street Waits to Hear the Numbers	07-11
Jefferies Adjusts Merck & Co.'s Price Target to $141 From $138, Keeps Buy Rating	07-11	MT
Merck: Jefferies raises TP after Verona acquisition	07-11	CF
Merck: FDA approval for Bravecto Quantum	07-11	CF
Merck: seeks FDA approval for new HIV treatment	07-11	CF
Merck Animal Health's Flea-and-Tick Treatment Approved in U.S.	07-10	DJ
Merck Animal Health Gets FDA Approval for Bravecto Quantum	07-10	MT
Fda approves Bravecto Quantum, a long-acting injectable for dogs 6 months and older	07-10	RE
Morgan Stanley Adjusts Price Target on Merck to $98 From $99, Maintains Equalweight Rating	07-10	MT
Global markets live: Nvidia, Tesla, Blackstone, BMW, Samsung…	07-10
AI Mania Masks Trade War Risks	07-10
U.S. FDA Accepts New Drug Application for Merck's Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection	07-10	CI
Merck Says FDA Accepts for Review New Drug Application for Doravirine/Islatravir to Treat HIV-1 Infection in Adults	07-10	MT
Merck : FDA to Review Doravirine/Islatravir Regimen in HIV-1 Infection	07-10	DJ
U.S. FDA accepts new drug application for Merck's doravirine/islatravir	07-10	RE
Deals of the day-Mergers and acquisitions	07-10	RE
Formycon tops SDax with news on FYB206	07-10	DP
Merck & Co snaps up respiratory drug maker Verona for USD10 billion	07-10	AN
Severn Trent "on track"; WPP makes non-exec next CEO	07-10	AN
PRESS DIGEST-British Business - July 10	07-10	RE
Merck shells out $10 billion for Verona in bid to diversify beyond Keytruda	07-09	RE